S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
Could This Be The Biggest Stock Of 2023? (Ad)pixel
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
Could This Be The Biggest Stock Of 2023? (Ad)pixel
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
Could This Be The Biggest Stock Of 2023? (Ad)pixel
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Could This Be The Biggest Stock Of 2023? (Ad)pixel
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
Could This Be The Biggest Stock Of 2023? (Ad)pixel
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
Could This Be The Biggest Stock Of 2023? (Ad)pixel
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
NASDAQ:ATHE

Alterity Therapeutics - ATHE Competitors

$2.71
+0.01 (+0.37%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.70
$2.98
50-Day Range
$2.61
$4.29
52-Week Range
$2.61
$8.73
Volume
1,592 shs
Average Volume
29,976 shs
Market Capitalization
$10.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

ATHE vs. AGRX, GLS, PULM, CNTX, HILS, GLMD, CING, ADIL, ERNA, and MRKR

Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Agile Therapeutics (AGRX), Gelesis (GLS), Pulmatrix (PULM), Context Therapeutics (CNTX), Hillstream BioPharma (HILS), Galmed Pharmaceuticals (GLMD), Cingulate (CING), Adial Pharmaceuticals (ADIL), Eterna Therapeutics (ERNA), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.

Alterity Therapeutics vs.

Agile Therapeutics (NASDAQ:AGRX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.

Agile Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

5.7% of Agile Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Alterity Therapeutics shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alterity Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 823.36%. Given Alterity Therapeutics' higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than Agile Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agile Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alterity Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Alterity Therapeutics has a net margin of 0.00% compared to Agile Therapeutics' net margin of -797.48%. Alterity Therapeutics' return on equity of 0.00% beat Agile Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Agile Therapeutics -797.48% -1,074.50% -186.41%
Alterity Therapeutics N/A N/A N/A

Agile Therapeutics received 420 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 69.87% of users gave Agile Therapeutics an outperform vote while only 66.67% of users gave Alterity Therapeutics an outperform vote.

CompanyUnderperformOutperform
Agile TherapeuticsOutperform Votes
422
69.87%
Underperform Votes
182
30.13%
Alterity TherapeuticsOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

Alterity Therapeutics has lower revenue, but higher earnings than Agile Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agile Therapeutics$4.10 million2.64-$74.89 million-$15.02-0.02
Alterity Therapeutics$3.37 million3.22-$9.32 millionN/AN/A

In the previous week, Agile Therapeutics had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Agile Therapeutics and 1 mentions for Alterity Therapeutics. Agile Therapeutics' average media sentiment score of -1.00 equaled Alterity Therapeutics' average media sentiment score.

Company Overall Sentiment
Agile Therapeutics Negative
Alterity Therapeutics Negative

Summary

Alterity Therapeutics beats Agile Therapeutics on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHE vs. The Competition

MetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$10.86M$5.44B$4.30B$5.80B
Dividend YieldN/A2.63%2.30%4.46%
P/E RatioN/A9.00123.5415.29
Price / Sales3.22292.843,518.3057.44
Price / CashN/A19.2719.7957.16
Price / Book0.424.124.475.01
Net Income-$9.32M$187.30M$115.28M$190.83M
7 Day Performance3.74%-2.86%-1.77%-0.94%
1 Month Performance-14.59%-10.76%-7.23%-6.87%
1 Year Performance-65.08%-15.36%-16.62%-19.16%

Alterity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGRX
Agile Therapeutics
1.8064 of 5 stars
$0.27
+12.7%
N/A-97.5%$10.84M$4.10M-0.0228News Coverage
Negative News
Gap Up
High Trading Volume
GLS
Gelesis
2.1584 of 5 stars
$0.15
-6.4%
$1.15
+689.8%
-97.3%$10.63M$11.19M0.002
PULM
Pulmatrix
1.9229 of 5 stars
$3.06
+1.0%
$10.00
+226.8%
-54.5%$11.14M$5.17M0.0024Analyst Report
News Coverage
CNTX
Context Therapeutics
2.331 of 5 stars
$0.66
flat
$4.00
+506.1%
-71.8%$10.54MN/A0.00N/ANews Coverage
HILS
Hillstream BioPharma
0 of 5 stars
$0.91
flat
N/A-36.3%$10.42MN/A0.001Upcoming Earnings
GLMD
Galmed Pharmaceuticals
1.8488 of 5 stars
$0.41
-4.6%
$5.00
+1,107.4%
-72.6%$10.39MN/A-0.4618Analyst Report
News Coverage
Gap Down
CING
Cingulate
0 of 5 stars
$0.91
flat
N/A-56.5%$10.29MN/A-0.5816Gap Up
ADIL
Adial Pharmaceuticals
2.0039 of 5 stars
$0.40
-2.4%
$3.00
+642.9%
-80.4%$11.52MN/A-0.5916Upcoming Earnings
Positive News
ERNA
Eterna Therapeutics
0 of 5 stars
$3.42
+4.0%
N/AN/A$10.05M$5.80M0.00N/AEarnings Report
News Coverage
Positive News
Gap Up
MRKR
Marker Therapeutics
1.7498 of 5 stars
$1.20
-31.8%
$1.50
+25.0%
+143.8%$10.03M$1.24M-0.2856Gap Down
High Trading Volume
This page (NASDAQ:ATHE) was last updated on 3/23/2023 by MarketBeat.com Staff